IRAK-1/4 Inhibitor I, >=98% (HPLC), solid

IRAK-1/4 Inhibitor I, >=98% (HPLC), solid

Application

IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines.

Biochem/physiol Actions

IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC50 values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested.

IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibitinhibitory effects on the nuclear factor (NF)-?B signaling pathway.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Solubility Form Assay Price Quantity
3573406 IRAK-1/4 Inhibitor I, >=98% (HPLC), solid off-white to light yellow 100 QTCFYQHZJIIHBS-UHFFFAOYSA-N 1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
£692.25 (exc VAT) per 25MG
-
+
3573407 IRAK-1/4 Inhibitor I, >=98% (HPLC), solid off-white to light yellow 100 QTCFYQHZJIIHBS-UHFFFAOYSA-N 1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
£253.50 (exc VAT) per 5MG
-
+